[go: up one dir, main page]

AR020601A1 - Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c - Google Patents

Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c

Info

Publication number
AR020601A1
AR020601A1 ARP990103374A AR020601A1 AR 020601 A1 AR020601 A1 AR 020601A1 AR P990103374 A ARP990103374 A AR P990103374A AR 020601 A1 AR020601 A1 AR 020601A1
Authority
AR
Argentina
Prior art keywords
peptides
proteins
telomerase
cancer
pharmaceutical compositions
Prior art date
Application number
Other languages
English (en)
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19902234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR020601(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of AR020601A1 publication Critical patent/AR020601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Proteínas o péptidos que activan la inmunidad mediada por las células T. y a vacunas contra el cáncer y composiciones para el tratamiento contra el cáncerque comprende tales proteínas o fragmentos de péptidos. Esta invencion también se refiere acomp osiciones farmacéuticas que comprenden las proteínas o péptidosy métodos para generar linfocitos T capaces de reconocer y destruir células tumorales en mamíferos. Proteína o péptido de telomerasa o un ácido nucleico capazde codificar unpéptido o pr oteina de telomerasa para utilizarse en un método de tratamiento o profilaxis del cáncer. En una configuracion preferida, el métodocomprende la produccion de una respuesta de células T contra la telomerasa.
ARP990103374 1998-07-08 1999-07-12 Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c AR020601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt

Publications (1)

Publication Number Publication Date
AR020601A1 true AR020601A1 (es) 2002-05-22

Family

ID=19902234

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990103374 AR020601A1 (es) 1998-07-08 1999-07-12 Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c
ARP100102596 AR077576A2 (es) 1998-07-08 2010-07-15 Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP100102596 AR077576A2 (es) 1998-07-08 2010-07-15 Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos

Country Status (20)

Country Link
US (2) US7030211B1 (es)
EP (4) EP1362597B2 (es)
JP (2) JP4618657B2 (es)
CN (1) CN100376290C (es)
AR (2) AR020601A1 (es)
AT (2) ATE247484T1 (es)
AU (1) AU756094B2 (es)
CA (2) CA2336743C (es)
CY (1) CY1109978T1 (es)
CZ (1) CZ303215B6 (es)
DE (2) DE69910580T3 (es)
DK (2) DK1093381T4 (es)
ES (2) ES2341170T5 (es)
HK (1) HK1039068B (es)
HU (1) HU230007B1 (es)
NO (1) NO313834B1 (es)
PL (1) PL203815B1 (es)
PT (2) PT1093381E (es)
TW (1) TWI261617B (es)
WO (1) WO2000002581A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19743497A1 (de) * 1996-10-01 1998-08-20 Geron Corp Katalytische Untereinheit menschlicher Telomerase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US7851591B1 (en) 1998-10-29 2010-12-14 Dana Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT
EP1171612A2 (en) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-specific cancer vaccine
JP2004527449A (ja) 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
FR2812087B1 (fr) 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
WO2004111075A2 (en) * 2003-03-05 2004-12-23 Dendreon Corporation Alternative reading frame polypeptides for treatment
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
WO2007094924A2 (en) * 2006-01-19 2007-08-23 The Regents Of The University Of California Human telomerase reverse transcriptase peptides
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
JP5207354B2 (ja) * 2008-03-12 2013-06-12 独立行政法人産業技術総合研究所 転写抑制ペプチド及びその遺伝子
ES2602453T3 (es) * 2008-06-16 2017-02-21 Mediolanum Farmaceutici S.P.A. Inmunoterapia antitumoral
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
CN110559422A (zh) * 2009-11-10 2019-12-13 急速制药公司 用于抑制细胞粘附至rgd结合位点或引导诊断剂或治疗剂至 rgd结合位点的方法
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
KR20130024888A (ko) 2010-02-16 2013-03-08 오슬로 유니버시티 하스피탈 에이치에프 폴리펩티드
FR2960542B1 (fr) 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
CN104080467B (zh) 2011-05-09 2020-09-15 急速制药公司 整联蛋白受体拮抗剂及其使用方法
EP2847213B1 (en) * 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
EP2875825B1 (en) * 2012-05-11 2017-12-13 KAEL-GemVax Co.,Ltd Composition for preventing or treating rheumatoid arthritis
CN116694597A (zh) * 2012-05-11 2023-09-05 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
JP6272853B2 (ja) * 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP2899201B1 (en) * 2012-09-19 2019-09-11 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
EP2899199B1 (en) * 2012-09-19 2019-07-03 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
EP2899200B1 (en) * 2012-09-19 2020-05-06 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102166542B1 (ko) 2012-09-28 2020-10-16 주식회사 젬백스앤카엘 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
CN102875657B (zh) * 2012-10-22 2014-04-09 南京工业大学 一种制备端粒酶多肽疫苗的方法
KR102093093B1 (ko) 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
KR102106756B1 (ko) 2012-12-13 2020-05-06 주식회사 젬백스앤카엘 자외선에 의한 피부 손상 예방 또는 치료용 조성물
US9907838B2 (en) * 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
TWI634210B (zh) * 2013-05-03 2018-09-01 傑姆維克斯＆凱爾有限公司 抑制熱休克蛋白質表現之胜肽及包含其之組成物
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
US10561703B2 (en) * 2013-06-21 2020-02-18 Gemvax & Kael Co., Ltd. Method of modulating sex hormone levels using a sex hormone secretion modulator
EP3020724A4 (en) * 2013-07-12 2017-01-18 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
EP3061459B1 (en) * 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (en) * 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
KR102106757B1 (ko) * 2013-11-29 2020-05-06 주식회사 젬백스앤카엘 난소 동결 보존용 펩티드 및 이를 포함하는 조성물
KR102667428B1 (ko) * 2013-12-10 2024-05-21 주식회사 젬백스앤카엘 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
CN105939723B (zh) * 2013-12-17 2020-02-28 珍白斯凯尔有限公司 前列腺癌治疗用组合物
KR102166549B1 (ko) 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CN106456697B (zh) * 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
CN105481949B (zh) * 2014-05-29 2019-11-12 施展 一种治疗癌症的肽变体及其应用
KR102166543B1 (ko) * 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102397510B1 (ko) * 2014-12-23 2022-05-13 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
JP7000161B2 (ja) 2015-05-26 2022-01-19 ジェムバックス アンド カエル カンパニー，リミティド 新規ペプチド及びこれを含む組成物
KR102638286B1 (ko) * 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20170054310A (ko) * 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
CA3039772C (en) 2017-01-06 2020-08-25 Eutilex Co., Ltd. Anti-human 4-1bb antibodies and uses thereof
CN110709094A (zh) 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
EP3630130B1 (en) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
EP4135759A4 (en) * 2020-04-17 2024-07-17 Lineage Cell Therapeutics, Inc. MHC-RESTRICTED TELOMERASE REVERSE TRANSCRIPTASE-SPECIFIC IMMUNOGENIC PEPTIDES
WO2024253422A1 (ko) * 2023-06-08 2024-12-12 주식회사 젬백스앤카엘 Gv1001를 포함하는 치주질환 및 치주질환에 의한 장애의 예방 또는 치료용 조성물
WO2025123055A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and associated methods for modulating weight gain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
ES2530769T3 (es) * 1994-06-14 2015-03-05 Univ Leland Stanford Junior Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
ES2184990T3 (es) * 1996-02-12 2003-04-16 Ml Lab Plc Nuevos metodos de vacunacion y vacunas para los mismos que comprenden un acido nucleico que codifica un primer epitope y un peptido que contiene un segundo epitope.
AU734196B2 (en) 1996-03-28 2001-06-07 Whitehead Institute Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
ATE295386T1 (de) * 1996-07-08 2005-05-15 Vivoxid Oy Bioabbaubares material mit hoher schlagzähigkeit
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
DE19743497A1 (de) * 1996-10-01 1998-08-20 Geron Corp Katalytische Untereinheit menschlicher Telomerase
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants

Also Published As

Publication number Publication date
CN1313773A (zh) 2001-09-19
US7794723B2 (en) 2010-09-14
PL203815B1 (pl) 2009-11-30
AR077576A2 (es) 2011-09-07
WO2000002581A1 (en) 2000-01-20
EP2316476A3 (en) 2011-09-14
HUP0104889A3 (en) 2004-04-28
DE69910580D1 (de) 2003-09-25
EP1362597B2 (en) 2014-06-25
JP5491315B2 (ja) 2014-05-14
DE69910580T3 (de) 2009-11-26
DK1362597T3 (da) 2010-06-14
EP2258383A2 (en) 2010-12-08
CZ200137A3 (en) 2001-06-13
EP1093381A1 (en) 2001-04-25
EP1093381B1 (en) 2003-08-20
DE69910580T2 (de) 2004-06-24
HK1039068B (zh) 2009-02-06
CZ303215B6 (cs) 2012-05-30
DK1093381T3 (da) 2003-09-08
ATE247484T1 (de) 2003-09-15
PL345541A1 (en) 2001-12-17
ATE458494T1 (de) 2010-03-15
ES2341170T3 (es) 2010-06-16
TWI261617B (en) 2006-09-11
EP1093381B2 (en) 2009-07-22
DK1093381T4 (da) 2009-09-21
ES2200526T3 (es) 2004-03-01
HU230007B1 (en) 2015-04-28
NO313834B1 (no) 2002-12-09
PT1093381E (pt) 2004-01-30
DE69942072D1 (de) 2010-04-08
ES2200526T5 (es) 2009-12-11
AU4534099A (en) 2000-02-01
EP2258383A3 (en) 2011-05-11
US20060106196A1 (en) 2006-05-18
NO983141L (no) 2000-01-10
CY1109978T1 (el) 2014-09-10
CN100376290C (zh) 2008-03-26
EP2258383B1 (en) 2016-03-09
US7030211B1 (en) 2006-04-18
JP2010252810A (ja) 2010-11-11
ES2341170T5 (es) 2014-09-09
HUP0104889A2 (hu) 2002-04-29
CA2336743A1 (en) 2000-01-20
AU756094B2 (en) 2003-01-02
EP2316476B1 (en) 2015-11-25
JP4618657B2 (ja) 2011-01-26
EP2316476A2 (en) 2011-05-04
CA2336743C (en) 2011-10-11
JP2002520293A (ja) 2002-07-09
PT1362597E (pt) 2010-04-14
EP1362597B1 (en) 2010-02-24
HK1039068A1 (zh) 2002-04-12
EP1362597A1 (en) 2003-11-19
CA2748996A1 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
AR020601A1 (es) Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c
ZA202306237B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
PT1171143E (pt) Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
ES2190799T3 (es) Inmunogenos peptidicos para vacunacion y tratamiento de la alergia.
DE69229428D1 (de) Therapeutisch nützliche peptide und peptidfragmente
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
NO20110429L (no) Polypeptider og nukleinsyre-DNA for anvendelse innen medisin
CL2019003409A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
EP1289551A4 (en) HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
MX2009003679A (es) Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores.
DE60118359D1 (de) Humanische pellino-polypeptide
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
PE20001287A1 (es) Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoral
AR028713A1 (es) Inmunizacion de ganado productor de leche con proteinas gapc quiméricas contra infecciones por streptococcus
WO2003093298A3 (en) Immunogenic peptides
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
ES2138574T3 (es) Composicion inmunogenica a base de particulas liberadas por el tumor.
BR0316722A (pt) Constructos genéticos e composições compreendendo rre e cte e usos destes
MX2024005408A (es) Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2.
WO2023196634A3 (en) Vaccines and related methods
WO2022094051A3 (en) Truncated modified recombinant adamts13 and uses thereof

Legal Events

Date Code Title Description
FG Grant, registration